| Similar Articles |
|---|
 |
The Motley Fool
July 1, 2009
Brian Orelli |
The Meat of a One-Drug Wonder AMAG announces that its iron replacement, Feraheme, was approved by the Food and Drug Administration.   |
The Motley Fool
July 25, 2007
Brian Orelli |
On to the FDA With a New Name After four phase 3 clinical trials, Advanced Magnetics is ready to submit a New Drug Application for ferumoxytol, and if all goes well, could have the product on the market by the end of next year. |
The Motley Fool
July 21, 2011
Brian Orelli |
AMAG-Allos, a Match Made in Necessity What do you get when you combine one unprofitable biotech, AMAG Pharmaceuticals, with another unprofitable biotech, Allos Therapeutics? |
The Motley Fool
August 13, 2007
Andrew R. Vaino |
Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow. |
The Motley Fool
December 27, 2007
Brian Orelli |
Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there. |
The Motley Fool
March 5, 2009
Brian Orelli |
5 Stocks to Benefit From China's Health-Care Plan Same idea, different country. |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
The Motley Fool
November 27, 2009
Brian Orelli |
Biotech Bargains for Your Portfolio Everyone is looking for bargains this time of year. That includes pharmaceutical giants looking to pick up some biotechs on the discount rack, and investors trying to get there first. |
